Passage Bio, Inc. (PASG)

Passage Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	29.05	41.58	49.34	60.06	30.11	6.95
Research & Development	56.12	61.42	86.05	117.67	81.79	29.74
Other Operating Expenses	-0.73	-0.94	0.73	8	1	0.5
Operating Expenses	84.44	102.06	136.13	185.73	112.9	37.19
Operating Income	-84.44	-102.06	-136.13	-185.73	-112.9	-37.19
Other Expense / Income	-	-	-	-0.34	-0.67	8.45
Pretax Income	-84.44	-102.06	-136.13	-185.39	-112.23	-45.63
Net Income	-84.44	-102.06	-136.13	-185.39	-112.23	-45.63
Shares Outstanding (Basic)	56	55	54	53	39	4
Shares Outstanding (Diluted)	56	55	54	53	39	4
Shares Change	3.07%	0.58%	2.03%	38.14%	811.60%	17.74%
EPS (Basic)	-1.53	-1.86	-2.50	-3.48	-2.91	-10.77
EPS (Diluted)	-1.53	-1.86	-2.50	-3.48	-2.91	-10.77
Free Cash Flow	-74.87	-78.41	-123.48	-152.52	-82.17	-41.09
Free Cash Flow Per Share	-1.33	-1.43	-2.27	-2.86	-2.13	-9.70
EBITDA	-80.89	-98.34	-132.45	-183.84	-111.43	-45.5
Depreciation & Amortization	3.55	3.72	3.68	1.54	0.8	0.13
EBIT	-84.44	-102.06	-136.13	-185.39	-112.23	-45.63

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).